SciSparc Ltd. (NASDAQ: SPRC) | Clearmind Medicine Inc. (Clearmind) (CSE: CMND) – Shares are up more than 70% this morning on recent news. $3.66 a share more than 6,000 trades
A recent reportfrom Data Bridge Market Research projected that the Global psychedelic drugs market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 13.3% in the forecast period of 2022 to 2029 and is expected to reach USD 8,020.01 million by 2029 from USD 2,992.51 million in 2021. The report said: “On the basis of source, the global psychedelic drugs market is segmented into synthetic and natural. In 2022, the synthetic segment is expected to dominate the global psychedelic drugs market as most of the products are made from chemicals that are man-made with very few products (such as psilocybin) made from natural ingredients.”
SciSparc Ltd. (NASDAQ:SPRC) BREAKING NEWS: SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment – SciSparc Ltd. , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or ” SciSparc “), today announced positive safety profile results from its joint pre-clinical trial with Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE:CWY0), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems. The trial tested the proprietary combination of SciSparc’s CannAmide with Clearmind’s psychedelic molecule, MEAI, for alcohol consumption.
Sparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment GlobeNewswire “Press Releases”
Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption
TEL AVIV, Israel , May 24, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive safety profile results from its joint pre-clinical trial with Clearmind Medicine Inc. (Clearmind) (CSE: CMND), (OTC: CMNDF), (FSE:CWY0), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems. The trial tested the proprietary combination of SciSparc’s CannAmide with Clearmind’s psychedelic molecule, MEAI, for alcohol consumption.
A histopathology assessment was conducted on several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland) from all experiment groups (n=3-5 per group) to determine the safety of the proprietary combination of MEAI and CannAmide versus control (mice) that were not exposed to alcohol). The severity of changes was scored by a 5-point scale by a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). The results indicated a high safety profile of the combination treatment with no treatment-related changes observed.
Oz Adler , SciSparc’s Chief Executive Officer, commented, “We are pleased with these latest results that confirm the high safety profile of the psychedelic combination treatment. Previous testing results showed high efficacy potential in treating alcoholism when using this combination. We plan on further exploring the safety and efficacy of combining our technology with Clearmind’s novel molecule.”
Previously announced successful results showed a significant dose dependent effect for the MEAI treatment in reducing alcohol consumption in treated animals, with additional significant effect when combining CannAmide with the lower sub-effective MEAI dose.
Results showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and higher (p0.01) compared to consumption before treatment. Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmide in addition to MEAI at a dose of 20 mg/kg compared to consumption before treatment. The mice were provided with 20% alcohol solution for 24 hours, three times a week, for seven weeks, and were treated every day with MEAI or MEAI/CannAmide during the last two weeks of alcohol treatment. The alcohol consumption was measured by weighing the alcohol bottles before and after; water consumption was measured similarly in parallel.
About SciSparc (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparcs focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.
About Clearmind Medicine
Clearmind Medicine is a new biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder, binge eating and depression.
The Israeli-Canadian company holds several patents for the non-hallucinogenic compound MEAI. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND”, the Frankfurt Stock Exchange under the symbol CWYO and on the OTC pink under the symbol “CMNDF”.
SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive safety profile results from its joint pre-clinical trial with Clearmind Medicine Inc. (Clearmind) (CSE: CMND), (OTC: CMNDF), (FSE:CWY0), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems. The trial tested the proprietary combination of SciSparc’s CannAmide with Clearmind’s psychedelic molecule, MEAI, for alcohol consumption.